Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462486 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 949
- Enrollment target
NCT02462486 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 949 participants.
The verdict
NCT02462486, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 949 participants
- Enrollment target
Study Summary
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
Interventions
- OTHER Sham Procedure
- DRUG Ranibizumab
- DRUG Abicipar Pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 949 participants |
| Start Date | 2015-06-25 |
| Est. Completion | 2019-06-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02462486
The ClinicalTrials.gov registry entry for NCT02462486 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 949 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham Procedure is the first listed.
NCT02462486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02462486 about?
NCT02462486 is a clinical study titled "Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration". This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
What is the current status of trial NCT02462486?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 949 participants. The study started on 2015-06-25. Estimated completion is 2019-06-06.
What interventions are being tested in trial NCT02462486?
The interventions under investigation include: Sham Procedure (OTHER), Ranibizumab (DRUG), Abicipar Pegol (DRUG).
Who is sponsoring clinical trial NCT02462486?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.